Samba Scientific’s Post

Could a patient’s gut microbiome influence how they will respond to immunotherapy? Watch an on-demand presentation by Rachel Newsome, PhD, featuring the findings from a study of Bacteroides-enhanced gut microbiomes associated with an enhanced response to anti-PD-1 therapy in NSCLC patients. In the talk, Rachel details how the characterization of live Bacteroides isolates led to the discovery of a novel influential metabolite that stimulates IFNγ in CD8+ T cells, and in combination with anti-PD-1 therapy, significantly reduces tumor growth in a NSCLC mouse model. Learn about the high-throughput isolation and cultivation methods that, not only enabled this discovery, but can empower any microbiome-based product or drug development program. Watch now! https://hubs.li/Q02nhmGJ0 #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector

🌍 This #WorldCancerDay, we want to spotlight how your #research can make a real difference! With every patient-derived sample you acquire from #CentralBioHub, you're not just buying a #biospecimen - you're unlocking potential! 🔬 Discover new biomarkers in these samples and re-innovate detection methods for tough-to-tackle cancers like ovarian and pancreatic #carcinomas! 💊 By studying how real #tumor cells react to drugs, your work paves the way for tailor-made treatments. Your research can help to provide individualized aid for each patient's needs. Every sample you explore leads to insights, breakthroughs, and lives changed. Let's outsmart #cancer together, one discovery at a time! Browse now our collection of Cancer Samples here: https://lnkd.in/dTv3HQbW #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine #CancerResearch

Thrilled to share our latest study, representing a fruitful collaboration with Prof Steve Evans and the talented Leeds microbubble team. Our work focuses on therapeutic microbubbles developed at Leeds, aiming to enhance the selective delivery of cytotoxic anti-cancer drugs to tumors. Through the application of a destructive ultrasound trigger, we've successfully released the cytotoxic payload within the tumor environment, thanks to the remarkable efforts of Amanda Race, Paul Loadman, and Nikki Ingram. Our study delves into the innovative use of an alternative maleimide–thiol linkage to connect liposomes (the carriers of cytotoxic drugs) to the microbubbles. Moreover, we've explored how this linkage impacts the distribution of drugs within the body, shedding light on novel avenues for targeted cancer therapy. To find out more, visit our website here https://lnkd.in/diBi-RN #CancerResearch #TherapeuticMicrobubbles #DrugDelivery #Innovation #Collaboration #ScientificBreakthrough

Latest DON Healthcare news First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer Adaptimmune’s Tecelra is the first TCR cell therapy to reach the U.S. market, but arrives with only modest sales expectations. The Food and Drug Administration on Thursday approved a new type of cellular medicine, clearing a therapy developed by the biotechnology company Adaptimmune for a rare soft tissue cancer called synovial sarcoma. The agency granted Adaptimmune’s therapy, formerly known as afami-cel and to be sold as Tecelra, an accelerated approval for use in some people with metastatic synovial sarcoma who previously received chemotherapy. Those people must have certain immune signatures and tumors expressing a protein, MAGE-A4, that Tecelra is designed to target. We are always looking for new possibilities in healthcare. If you are a decision-maker, submit your opportunity via this link: https://lnkd.in/eQcjSSWk Help us build a network that can make a real difference to people's health. Join our FREE Healthcare platform today - www.don-healthcare.com #Innovation #BioTech #CancerResearch #FutureofMedicine

Researchers have developed a method to co-deliver ionizable drugs and siRNA directly into patient cells, enhancing stability and efficiency. This innovation could revolutionize treatments for complex conditions like cancer and viral infections by enabling targeted therapy. Read the full article here: https://lnkd.in/ekGQC_2H #DrugDelivery #DrugDevelopment #GeneTherapy #TargetedTherapy #Biotechnology #Pharmacology

Could a patient’s gut microbiome influence how they will respond to immunotherapy? Join Rachel Newsome, PhD, from Dr. Christian Jobin's lab at the Univ. of Florida, for a webinar on Feb. 21st featuring the findings from a study of Bacteroides-enhanced gut microbiomes associated with an enhanced response to anti-PD-1 therapy in NSCLC patients. Characterization of live Bacteroides isolates led to the discovery of a novel influential metabolite that stimulates IFNγ in CD8+ T cells, and in combination with anti-PD-1 therapy, significantly reduces tumor growth in a NSCLC mouse model. Save your seat for this informative discussion and learn about the high-throughput isolation and cultivation methods that, not only enabled this discovery, but can empower any microbiome-based product or drug development program. Register here:  https://lnkd.in/g8dJcFYb #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector

We aim to deliver the most innovative, treatment-directing testing possible while providing analytical approaches that lead the way for personalised medicine and translational science. At Pierian Biosciences we have implemented 2 platforms to aid in the testing, analysis, and evaluation of tumour samples. ImmunoINTEL - a flow cytometry-based platform providing phenotypic characterisation and quantitative functional interrogation of tumour and immune populations within a tumour sample and relevant tissue. ChemoINTEL - is a functional multi-parametric chemo-sensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumour cells (dissociated solid tumours or hematologic cancers) induced by cytotoxic agents, targeted molecular therapeutics, biologics, or combination therapy. Pierian Biosciences is dedicated to providing clinically actionable diagnostic information enabling healthcare providers to personalise treatment of patients with cancer and auto-immune disease. #chemotherapy #immunotherapy #cancerresearch #bioscience #healthcare

We aim to deliver the most innovative, treatment-directing testing possible while providing analytical approaches that lead the way for personalised medicine and translational science. At Pierian Biosciences we have implemented 2 platforms to aid in the testing, analysis, and evaluation of tumour samples. ImmunoINTEL - a flow cytometry-based platform providing phenotypic characterisation and quantitative functional interrogation of tumour and immune populations within a tumour sample and relevant tissue. ChemoINTEL - is a functional multi-parametric chemo-sensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumour cells (dissociated solid tumours or hematologic cancers) induced by cytotoxic agents, targeted molecular therapeutics, biologics, or combination therapy. Pierian Biosciences is dedicated to providing clinically actionable diagnostic information enabling healthcare providers to personalise treatment of patients with cancer and auto-immune disease. #chemotherapy #immunotherapy #cancerresearch #bioscience #healthcare

#CentralBioHub's Peripheral Blood Mononuclear Cell Samples At Central BioHub, we're thrilled to offer researchers an extensive collection of Peripheral Blood Mononuclear Cell (PBMC) samples. From vaccine development to cancer immunotherapy, our PBMC samples play a crucial role in advancing scientific understanding. With state-of-the-art cryogenic storage facilities maintaining temperatures between -80° to -196° C, our PBMC samples boast unparalleled quality, viability, and functionality. Explore the possibilities, advance your experiments, and accelerate scientific progress. Find PBMC research samples in our inventory: https://lnkd.in/eHc_XKAy Sample Specifications: •               Up to 100M Cells •               PBMC Cells | Pellets | Pools •               Storage Temperature: -80° to -196° C •               Diagnosis: Cancer | Autoimmune | Healthy Donor #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine #PBMC_Samples

Could gut bacteria influence immunotherapy outcomes? Join our webinar with Rachel Newsome, PhD on Feb. 21 to learn about an exciting study linking improved anti-PD-1 therapy response in NSCLC patients to a gut microbiome enhanced with Bacteroides species. A novel Bacteroides metabolite was discovered that stimulates IFNγ production in CD8+ T cells and, when combined with anti-PD-1 treatment, reduced NSCLC tumors significantly in a mouse model. Learn about the cultivation methods that enabled this discovery and empower other microbiome-based drug development. Make sure to save your seat for this informative discussion:  https://hubs.li/Q02kgmYw0  #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector